explore -WSS

explore

author：comprehensive 2025-09-27 12:56:25 - browse：688

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Medicare innovation center doesn’t save money, experts say

hotspot

explore

WSS

Key House Republican on health care plans exit from Congress

Readout LOUD podcast: How biotech is using artificial intelligence

The biotech scorecard for Q4: 16 stock

The United States is paying nearly triple for new Covid vaccines

European officials brace for rough respiratory virus season

PhRMA lawsuit over Medicare drug price negotiation tossed

entertainment

explore

entertainment

Walensky prepares to leave CDC — and Congress — behind

Vaccine advisory panel ACIP left half staffed by HHS

Alkermes shareholders re

6 solutions to address cancer drug shortages and others

Walensky prepares to leave CDC — and Congress — behind

KalVista pill reduced swelling 'attacks' caused by genetic disease

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast: How biotech is using artificial intelligence

hotspot

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Experts study whether long Covid risk adds up with each reinfection

Medicare Advantage proposed rates disappoint insurers

IVG is promising — but it won’t replace IVF quite yet

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

What should King Charles tell the public about his cancer?

explore

hotspot

explore

explore